Phase 2 Randomized Study of Different Neoadjuvant Regimens in Subtypes of Breast Cancer
试验速览
- 阶段
- 2 期
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- pathological complete response(pCR) rate of breast and axilla after surgery
研究概览
简要总结
There are no standard neodjuvant regimens adapted according to the different subtypes of breast cancer. This is a phase 2, randomized study to evaluate several regimens in different subtypes of breast cancer.
详细描述
Breast cancer is a heterogenous disease with at least 4 intrinsic subtypes including Luminal A, Luminal B, HER2 enriched, Basal-like and normal breast like. Different subtypes have different prognosis and treatment sensitivity. Thus, it would be more suitable to administer different chemo-regimen in different subtypes. This is especially true in neoadjuvant chemotherapy setting where no standard regimen has ever been established. Therefore, we designed this phase 2 randomized clinical trial to explore potential effective regimens in variable subtypes of breast cancer in neoadjuvant treatment. Patients were first classified into Luminal type, Her2 positive type and triple-negative type by immunohistochemistry exam of ER/PR/HER2 in core needle biopsy and then randomized to received either dose dense paclitaxel in Luminal type or dose dense paclitaxel plus carboplatin with or without trastuzumab in HER2 positive type or dose dense paclitaxel plus carboplatin in triple-negative type.The control groups in each subtype all receive paclitaxel plus epirubicin every 3 weeks. The duration of treatment is 4-6 cycles. Primary endpoint is the pathological CR rate in each subtypes. Secondary endpoints include disease free survival, objective response rate, safety. Tissue samples and blood samples will be collected at baseline and during treatment. There will be exploratory biomarkers analyses to identify predictive markers for efficacy in every subtypes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Stage IIa-IIIc breast cancer patients plan to receive neoadjuvant chemotherapy
- •Patients have enough tissue sample to do IHC test for subtype classification
- •Patients have at least one measurable lesion according to RECIST1.1
- •No prior treatment for breast cancer
- •Adequate bone marrow (neutrophil count ≥1500 ml and platelet count ≥100,000 ml), renal (serum creatinine <1.5 times the upper limit of normal [ULN] or a creatinine clearance of ≥60 ml/minute), hepatic (total bilirubin ≤1.5 ULN; alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase ≤2.5 ULN), and cardiac function (assessed by electrocardiogram or thoracic radiography) were required.
排除标准
- •Fertile women were excluded if pregnant or lactating or if they were not using adequate contraception.
- •Previous chemotherapy for breast cancer.
- •history of other serious illness (e.g. congestive heart failure, angina pectoris, uncontrolled hypertension or arrhythmia, clinically significant neurologic or psychiatric disorders, uncontrolled serious infection, AIDS), had an organ allograft, severe gastrointestinal disorder, or other neoplasias (except for in situ cervical cancer, non-melanoma skin cancer, or previous diagnosis of cancer with no evidence of disease for >10 years).
研究组 & 干预措施
Luminal subtype test
Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
干预措施: Paclitaxel (Drug)
Luminal subtype control
Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
干预措施: Epirubicin and Paclitaxel (Drug)
Her2 positive subtype test
Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
干预措施: Paclitaxel and carboplatin (Drug)
Her2 positive subtype control
Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
干预措施: Epirubicin and Paclitaxel (Drug)
Triple negative subtype test
Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
干预措施: Paclitaxel and carboplatin (Drug)
Triple negative subypte control
Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
干预措施: Epirubicin and Paclitaxel (Drug)
结局指标
主要结局
pathological complete response(pCR) rate of breast and axilla after surgery
时间窗: 3 years
pathological complete response(pCR) of breast and axilla after surgery means after operation, no invasive component can be found in both breast and axillary lymph nodes. The pCR rate is calculated by number of patients having pCR after sugery divided by number of patients receiving neoadjuvant chemotherapy.
次要结局
- Disease free survival(3years and 5years after operation)
- Overall survival(3 years and 5years after operation)
- Adverse event(during screening and treatment, withing 21 days after day 1 of last cycle)
研究者
Binghe Xu
MD, professor and Director of Department of Medical Oncology
Chinese Academy of Medical Sciences